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Abstract 
Background: There has been little detailed systematic consideration of the delivery, setting and 
outcomes of paediatric OPAT, although individual studies report that it is a safe and effective 
treatment. 
Objective: This scoping review examined what is known about the delivery, settings and outcomes of 
paediatric OPAT and to identify key knowledge deficits. 
Design: A scoping review using Arksey and O’Malley’s framework was undertaken.  
Data sources: Key words were identified and used to search MEDLINE and CINAHL.  
Study appraisal methods: Primary research studies were included if samples comprised children and 
young people 21 or under, who had received OPAT at home or in a day treatment centre. The Mixed 
Methods Appraisal Tool (MMAT) was used to review the methodological quality of the studies 
Main findings: From a preliminary pool of 157 articles, 51 papers were selected for full review. 19 
studies fitted the inclusion criteria. Factors influencing delivery of OPAT were diverse and included 
child’s condition, home environment, child-related factors, parental compliance, training, and 
monitoring. There is little consensus as to what constitutes success of and adverse events in OPAT.  
Conclusions: Future studies need to clearly define and use success indicators and adverse events in 
order to provide evidence that OPAT is safe and effective. 
Implications: Consensus outcomes that include child and parent perspectives need to be developed 
to allow a clearer appreciation of a successful OPAT service. 
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Background 
Children with serious bacterial infections (SBIs) have been treated using parenteral antimicrobial 
therapy in an outpatient setting since the mid-1970s 1. At this time, the intramuscular route was 
considered to be a clinically safe and largely successful means of treating infection 2. However, 
advances in intravenous therapy and the requirement to protect children from the pain associated 
with the intramuscular injections led this route to fall into disfavour.  
More recently, OPAT has been defined as the parenteral administration of antimicrobials for at least 
two consecutive days without an intervening hospitalisation 3. This treatment is selectively offered 
to treat SBIs such as pneumonia 4, osteoarticular infections (OAIs) 5 and low risk febrile neutropenia 6. 
Depending on the child’s condition at presentation, the child may be admitted to hospital and 
receive initial treatment and monitoring until deemed sufficiently stable to be discharged home on 
OPAT, or the child may be referred immediately for OPAT without ever having been admitted to 
hospital.  
Two main approaches to OPAT delivery are used depending on the local resources available. The first 
is ambulatory and requires the child to return to a clinical setting (e.g., emergency department or 
day treatment centre) on a daily (or more frequent) basis for assessment and administration of the 
therapy 7,8. The second approach is home-based, with the child being assessed and the therapy 
administered in the child’s home either by nursing staff or by their parents who have been trained to 
assess and administer the antibiotics 4. When the service is delivered by nurses this is usually 
undertaken by those who are either part of a specialised OPAT team of community nurses 9,10, or 
those within a broader community role such as ‘hospital at home’ 11,12.  
A variety of patient and health care benefits are potentially associated with OPAT; most notably for 
health services is that OPAT is considered to be a more cost-effective option when compared to 
continued inpatient care 13. Other benefits include “parent and patient satisfaction, psychological 
well-being, return to school/employment, reductions in healthcare-associated infection and cost 
savings” (Patel et al., 2015, p361).  
Given that there has been little consideration of the direct and indirect benefits, disadvantages and 
broader outcomes of OPAT, a scoping review was conducted to examine what is known about OPAT 
in terms of delivery, settings and outcomes, and to identify key areas of deficits in knowledge. 
Specifically, this scoping review explored primary research that examined OPAT delivered to children 
and young people aged 21 or under, who had received OPAT in a home or day treatment centre, of 
which at least 80% of treatment was intravenous. 
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Method 
A scoping review was undertaken as the intention was to explore and map the key concepts and to 
identify gaps in research related to OPAT. The scoping review was conducted following Arksey & 
O’Malley's (2005) framework 14, which was modified to allow more flexible and robust reporting of 
the results 15–17. These modifications included: 1) an iterative approach to refine our  search strategy 
and inclusion criteria; 2)  an assessment of methodological quality was undertaken using the Mixed 
Methods Appraisal Tool (MMAT) 18; and 3)  in the absence of EQUATOR guidance on reporting we 
were guided by recommendations made by the Joanna Briggs Institute 19. 
Inclusion Criteria and Types of Sources 
The inclusion and exclusion criteria are shown in Table 1. No date restrictions were applied to the 
search.  
Table 1: Inclusion and Exclusion Criteria 
Inclusion criteria  Exclusion criteria 
1. Primary research studies  
2. Articles in peer-reviewed journals 
3. Published in English 
4. Data is presented from children and young 
people aged 21 years or under (and is 
reported separately from adult’s data) 
5. Children and young people who received 
OPAT treatment did so in their home or a 
day treatment centre and data from 
inpatients and outpatients were reported 
separately. 
6. Children and young people received  
at least 80% of treatment intravenously.  
7. Data from intramuscular and intravenous 
treatment reported separately. 
1. Studies conducted in 
developing/low income settings 
2. The full text of the article was 
unavailable 
3. Case studies, reviews, guidelines, 
poster, abstracts, commentaries 
and editorials. 
 
 
The search terms were generated based upon consideration of: the population (children and young 
people under the age of 21 years), the “concept” under investigation (parenteral antimicrobial 
treatment) and the context (home-based or outpatient-based care). Key words and terms identified 
by the authors were used to search PubMed and CINAHL. Further key words were then identified 
and the new search list was used to search Google Scholar to generate a comprehensive final set of 
search terms (Table 2).  
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Table 2: Search terms (by population, concept, context). 
pOPAT  
OR  
paediatric 
outpatient 
parenteral 
antimicrobial 
therapy 
Population 
(<21 years) 
• Paediatric OR pediatric OR infant OR child* OR adolesce* 
• Infection OR infectious disease 
Concept 
(Intervention) 
• Antibiotic OR antimicrobial AND (agent OR therapy OR prescri* OR 
manage*) 
• Parenteral OR intravenous infusion OR home infusion 
Context 
(Setting) 
• Outpatient OR home OR ambulatory OR community 
Search Strategy 
Major databases consulted for the indexed published literature were MEDLINE and CINAHL. Further 
articles not identified in the results of the above strategies were added if identified by other means 
(e.g. cited by a related article, identified on a World Wide Web search). The search was initially 
undertaken February 2017 and updated in July 2017 and was supported by an expert librarian (full 
electronic search strategy available upon request). A data extraction sheet was developed and 
iteratively refined and included the following broad categories: delivery, setting and outcomes. In 
line with the aims of a scoping review, all outcomes of paediatric outpatient treatment were 
included in the data extraction sheet. 
Appraisal of study quality 
The Mixed Methods Appraisal Tool (MMAT) 18 was used to review, but not score, the methodological 
quality of the studies. In seven of the 19 studies, it was not completely clear that the collected data 
adequately allowed the research question to be answered. Other key quality issues related to 
completeness of outcome data, appropriateness of measurements and acceptability of response 
rate (see Table 3).  
Table 3: MMAT Synthesis Table 
Type of 
study 
Methodological 
quality criteria 
 RCT Quantitative descriptive 
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N = No, Y = Yes, UC = Unclear 
 
Results 
Overview of the Studies 
A preliminary pool of 157 articles were identified. Titles and abstracts were reviewed by two lead 
reviewers and where there was disagreement a third reviewer was used; 51 papers were selected 
for full review, from which 19 were identified as having good fit with the inclusion criteria and the 
objective of the review (see Figure 1: Flow diagram).  
 
 
 
 
question
s 
Do the data 
address the 
research 
question?  
Y Y Y Y Y Y UC UC  Y UC UC  Y Y Y Y UC UC UC 
2. RCT Is there a 
clear 
description of 
randomizatio
n? 
Y Y                  
Is there a 
clear 
description of 
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N N                  
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complete 
outcome 
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Is there low 
withdrawal? 
Y Y                  
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strategy 
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Is the sample 
representativ
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Are 
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s 
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Figure 1: Flow Diagram for scoping review process (from JBI Manual).  
 
A condensed summary chart detailing the study design, sample, requirements, setting and delivery 
of the 19 studies included in the review is available as a supplementary file.  The review of studies 
via the MMAT revealed the quality as fair (see Table 3).  
Data were international, reporting on studies undertaken in the United States 5,8,10,13,22,24–26, Canada 
6,7,9, Spain 11,23, Australia 12,21, Ireland 4, India 20, , Israel 27 and The Netherlands 28. 
The studies included in the review had adopted a record review design with the exception of 3 
cohort studies 7,11,12, 2 randomised control trials 20,21, an online survey 22 and a pilot programme 6.  
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All study populations comprised children and/or young people aged 1 week to 21 years, with the 
exception of one study which presented data from an online survey of paediatric physicians 22. 
Sample sizes ranged from 7 28 to 2687 24.  
Delivery of service: target population, indications for treatment, factors influencing 
delivery  
The studies were mixed in terms of whether the studied cohort had a common underlying condition 
as well as the infective indication for receiving OPAT. Only 4 studies had a specific focus on one such 
condition: cancer 6,21 and cystic fibrosis 4,28. The remaining studies had either no specific underlying 
condition reported 5,7–10,24–26 or the children had a range of underlying conditions (such as 
gastrointestinal diseases and HIV infection) 11–13,20,22,23,27. 
In terms of the infective indications for treatment, half of services delivered OPAT for a wide range 
of infection (e.g. respiratory, blood stream, urinary, and musculoskeletal) 8,10–13,22,24–26. The remaining 
half were focused on a single indication for treatment, such as urinary tract infections 4–7,9,20,21,23,27,28.  
The key consideration in determining the suitability of the child for OPAT was the presence of 
infection. Other factors included the stability of the child’s condition 7,9,11,20,23 and the home 
environment, either in generic terms 22 or more specifically such as the need for the home 
environment to be ‘stable’ 10and appropriately resourced in terms of refrigerator and/or telephone 
8,10,11,20,21. The location of the home was specifically reported as influential in determining access to 
pOPAT by four studies 11,20,21,27 and, although, this was not clearly reported it is likely that this was 
relevant in other studies where specialist home-based teams delivered pOPAT.  
Parental compliance/reliability was also reported as either an inclusion factor 8,11,20,22 and/or the lack 
of these qualities as an exclusion factor 9,10. Parents were trained to administer medication to their 
child in 6 studies 4,6,11,23,25,27. In all of these studies, all children had a pre-existing condition. However, 
even when professionals were responsible for the administration of medication, parents received 
training to: assess for complications  4,10,11,25,28; to check the child’s temperature 9,20, deterioration 27; 
inspect the IV site 8 and troubleshoot 6. Five studies reported that training parents required a period 
of time in hospital before discharge to pOPAT 4,10,11,25,28 and one study reported that a period of 
hospitalisation was needed to check for drug reactions 26.  
Support for parents or carers varied across the studies depending on whether the child was receiving 
home-based or ambulatory care. For children in the home setting, support varied from daily phone 
calls and home visits as needed 11, initial daily or twice daily visits 12,21,25, visits about every 2.9 days 27 
and 24-hour access to professional support 4–6,27. For children receiving ambulatory-based OPAT, 
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parents were advised to return to the emergency department and/or readmitted if they had 
concerns 8,21. 
Setting 
In most studies, the family home was the setting for the delivery of OPAT 4,6,10–13,21,23,25–28. The 
remaining studies were set in various outpatient settings: day treatment centres 7,9, a combination 
of hospital outpatient/local clinics 20, or emergency department 8. In 3 studies the location was not 
reported or unclear 5,22,24. Little detail was provided about the outpatient settings or the actual 
suitability, difficulties or challenges of the home as a setting for OPAT. 
Outcomes  
No studies reported a priori criteria for success of paedeatric OPAT. “Success” was therefore implied 
in terms of the percentage/number of children completing OPAT as home-based or outpatients 13 or 
through reports of what percentage of episodes of treatment were completed at home 11. Other 
studies claimed that home treatment improved the child’s condition compared to previous hospital 
based courses of treatment 28, or implied success through noting that all ambulatory patients 
returned for scheduled re-evaluation within 24 hours of commencing OPAT/ initial discharge 8.   
Clinical complications such as line failures, rehospitalisation and adverse drug reactions were not 
consistently reported as adverse events although these have been identified as such in the Summary 
Chart.  
The reporting of hospitalisation/re-admission was inconsistent. Although some studies reported the 
number of children who were hospitalised after commencing OPAT 3, 7, 9, 10, 11, 12, 13, 20, 21, 25, 26, others 
reported the number of treatment courses that required unplanned hospitalisation 5, 23, 24. 
Hospitalisation rates varied ranging from 4% 12  to 22% 27 of patients and between 26% 5 and 29% 25 
of courses. Children were hospitalised as a result of being ‘unresponsive to treatment’ (22%) 27; 
‘inadequate clinical response’ (1%) 12; ‘exacerbation of underlying condition’ (7%) 11 and ‘poor 
evolution of infectious disease' (3%) 11, ‘deterioration’ (0.6%)4, fever 20, 23 and the need to ‘complete 
course of IVs’ 25. Catheter associated complications were also linked to hospitalisation 5, 13, 23, 24, 26. 
Other reasons for hospitalisation included ADRs and surgical management 5, 24, seizures and bleeding 
20, gastro-oesophageal reflux and positive blood culture result 9. In two studies the reason for 
admission was less clear 7, 10. Unplanned medical care visits were reported in two studies with 17 out 
of 98 (17%) children having an unplanned visit 26 and 17 (48%) having one or more unplanned visits 
10.  
The number of other catheter related complications was reported by 5 studies5,12,25–27; only one 
study reported no catheter-related complications 6. Extravasation, displacement and other 
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intravenous access issues were reported by 5 studies 7–9,11,28 . Poor technique and/or technical 
problems were reported by 2 studies 11,28.  
The definitions and reporting of adverse drug reactions (ADRs) was inconsistent between studies. In 
four studies reported that no ADRs occurred 6,8,21,27, and others provided generic reports of ADRs. 
For example, 25% of children experiencing pOPAT complications were reported as being associated 
with the use of highly bioavailable antibiotics 24. Two studies (11%) provided more detailed reports 
of ADRs: in one study, 70 (29%) of courses were deemed to an ADR and of these early 
discontinuation of antibiotics was report in 58 courses of treatment 25 and in the other study 
reported ADRs were associated with inappropriate choice of drug (6%) and inappropriate dose or 
duration of treatment (26%), although the authors also reported that no adverse antibiotic-related 
events necessitated change or cessation of antibiotic or hospital readmission 12.  
Seven studies reported on satisfaction (parental satisfaction 6,7,21,27,28; children’s satisfaction 27,28), 
although the mechanisms of data collection were often unclear or unreported. In one study some 
parents (32%) were worried about taking their febrile child home and 20% were worried about 
taking their child home with indwelling IV access 7. In another study, some mothers of children aged 
6-12 years were anxious about accepting the responsibility of their child’s treatment and concerned 
about the stress that home-based care would create for the family 28. The 12-18 year olds in this 
study described liking home-based care due to the lack of disruption to home and school life, but 
reported missing the contact with staff and other patients that occurred when they were inpatients. 
In another study, children aged 10 or over completed questionnaires assessing their quality of life: 
Those who were treated at home had significantly better appetites and slept better compared to 
those who were treated in hospital 21. 
Six studies concluded that OPAT is more cost effective than conventional inpatient treatment 6,7,11–13 
6,7, 10-13; two studies notes that the cost effectiveness calculations did not account for the costs 
associated with complications 10 or the direct cost to families 6.  
Discussion   
This scoping review has systematically examined the empirical evidence regarding the delivery, 
settings and outcomes of OPAT. The quality review revealed that the studies are generally fair 
quality. The operationalisation of specific definitions/ treatments varied widely and the reporting of 
who gave treatment and the setting was often unclear.  
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The factors influencing the delivery of OPAT were diverse and included: service-related issues 
including staffing and monitoring; child-related factors such as age, nature of infection, clinical 
status; and home/parent related factors such home environment, parental compliance, and training.   
In a systematic review comparing home-based versus hospital-based treatment with intravenous 
antibiotics in children, the authors concluded that data about the safety of treatment was scarce 29. 
In addition to a scarcity of data, this review found that there is a lack of clarity and consensus as to 
what constitutes success in OPAT making comparison across studies difficult; however, individual 
studies report that OPAT is safe 5–7,12,27. There is also a lack of clarity and consensus in the definition 
and reporting of adverse events. There was little acknowledgement that although problematic, 
defining adverse events is necessary or acknowledging that for one type of AE – ADRs - objective 
criteria do exist and could be used. Conclusions about the success of OPAT have been drawn despite 
evidence of adverse events (which were ill defined yet occurred in most studies) and readmissions 
(which were reported in different ways, and likewise occurred in most studies).   
In terms of key knowledge deficits within the literature we scoped for this review, most of the 
studies were retrospective and follow-up data examining health outcomes over time are lacking. We 
also know little about parents and children’s experience of OPAT. There is little reflection about the 
factors which may influence experience such as the child’s age, nature of infection, family 
circumstances and the educational level of parents. Additionally, considering the fact that infection 
has a higher incidence in families of lower socio-economic status 30,31, there is little detail about 
whether these families are excluded from OPAT or, if in receipt, how they fare in comparison to 
families in better circumstances. We know little of children who were not selected for OPAT or 
parents and children who declined this treatment and the reasons why. In agreement with the 
recent systematic review comparing home-based versus hospital-based treatment, we likewise 
conclude that although studies report patients to be safely treated at home, generalisation to all 
patients is difficult due to selection bias 29 
The evidence base for the economic benefits of OPAT is poorly and inconsistently presented and 
does not take account of any shift of economic burden onto the families. 
Strengths and Limitations 
This scoping review has used a robust and iterative methodological approach and included an 
analysis of study quality. However, the variable quality of the evidence base means that strong 
conclusions regarding the delivery, settings and outcomes of OPAT cannot be made. Conclusions are 
also complicated to draw due to the diversity in terms of the age of children receiving treatment, 
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children’s underlying conditions, indications for treatment and the delivery of treatment. Our focus 
was outpatient care therefore our findings do not reflect comparison with inpatient care.  
Implications for research  
Future studies need to clearly define success indicators and adverse events in order to substantiate 
claims that paediatric OPAT is safe and effective. Specifically, hospitalisation, unexpected catheter 
related complications, extravasation, and antibiotic complications should be reported as adverse 
events. To allow comparison between studies and pooling of data from different cohorts, the 
definitions for such AEs need to be agreed by healthcare professionals delivering adult and 
paediatric OPAT care. 
Numerous knowledge deficits need to be addressed. There is a need for follow-up data tracking the 
trajectory of patient’s interactions with health care providers over time. Future research of a 
qualitative nature needs to be conducted with children and young people receiving OPAT, and their 
parents in order to explore their experiences of receiving this treatment. A thorough cost-benefit 
analysis needs to conducted that includes a consideration of the economic impact on the family. 
Implications for practice  
Parental and child perspectives should be sought to identify how they can best be supported. 
Despite the apparent professional confidence in the success and benefits of paediatric OPAT, it 
should not be assumed that all families will choose OPAT or that it will be the most appropriate 
intervention. Clear, consensus outcomes that include outcomes of importance to the children and 
their parents need to be developed to allow a clearer appreciation of a successful OPAT service. 
Strengths and limitations of this study 
• Identification of methodological weaknesses in studies 
• Identification of gap in knowledge about parents and children’s experience of OPAT, the lack of 
predetermined success criteria and clarity about what constitutes an adverse event. 
• Due to the variable quality of the evidence base, strong conclusions regarding the delivery, 
settings and outcomes of OPAT cannot be made. 
Conclusion 
Further work that includes the perspectives of children and parents and which uses clearly defined 
indicators will improve the evidence base for the efficacy and safety of paediatric OPAT.  
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Banerjee 
et al. 
(2014) 
 
USA 
 
 
 
 
 
 
Online survey of 
paediatric 
physicians (survey 
open for 2 
months) 
 
158 physicians 
 
Child’s age = NA 
 
 
Underlying condition  
• Various but not 
reported. 
Indication for treatment 
• Most commonly 
osteomyelitis, 
endovascular central 
nervous system 
infections, pneumonia 
Inclusion criteria 
• Patient compliance, home 
environment, 
• Need for parenteral medication  
• Resources for follow-up/ 
monitoring 
• Patient age 
• Presence of bacteraemia 
 
Setting  
• Not reported 
Delivery  
• Most (94%) reported 
that their institution had 
a team for peripherally 
inserted central catheter 
placement.  
 
 
Adverse events 
• 104 (67%) respondents reported that line or drug-
associated complications occurred in 10% or fewer 
cases. 
 
 
 
 
Financial 
• Revenue sources reported to 
support OPAT management 
included: outpatient visit 
charges (51%), inpatient consult 
charges (36%), support from 
hospital or healthcare system 
(18%), support from home care 
agency (12%), or income from 
infusion center (4%).  
• 32% of respondents did not 
know the revenue source for 
OPAT management and 5% 
reported OPAT services were not 
financially supported. 
 
• Responses regarding OPAT 
programs and clinical 
practice, may not represent 
actual practice.   
• Responses may be subject 
to recall bias.  
• The generalizability 
of the findings to all 
pediatric ID practices 
is uncertain.  
• No assessment of 
the extent to which 
OPAT use varied by 
the presence of 
comorbidities.  
• Survey did not 
collect data on all of 
the clinical and 
social factors that 
contribute to 
decision making 
regarding OPAT use. 
• OPAT use in paediatrics is 
common.  
• Most respondents 
significantly underestimated 
the risk of OPAT-related 
complications. 
• Substantial variation in the 
characteristics of pOPAT 
practices and frequency of 
OPAT use.  
• Many pOPAT programs may 
lack adequate resources and 
infrastructure to perform 
appropriate follow-up of 
OPAT patients.  
• Better evidence is needed 
regarding not only the 
benefits of pOPAT. 
• Decisions to use OPAT are complex, 
and reasons for the variability in 
OPAT use by pediatric ID providers 
should be further explored. 
Campo et 
al. (2001) 
 
Spain  
 
 
 
Retrospective 
review (6 years) 
 
7 children 
receiving home 
parenteral 
nutrition 
(and 11 adults, 
whose data are 
not reported 
here). 
 
Mean age 3.1, 
Range 6 months-8 
year. 
Underlying condition 
• Intractable diarrhoea, 
short bowel, motility, 
liver cirrhosis. 
Indication for treatment 
• Catheter-related 
infection  
Inclusion criteria 
• Existing CVC for infusion of 
HPN  
• All the HPN patients/ families/ 
caregivers competent in 
handling CVC and avoiding and 
recognising complications.  
 
Setting  
• Home 
Delivery 
• Infusion performed after 
completion of HPN. 
• If the patient's general 
condition was stable, the 
whole therapy could be 
received at home. 
Otherwise, the patient 
remained in hospital 
until complete remission 
of fever occurred and 
sensitivities were 
known. 
 
Key clinical outcomes 
• No differences in the length of antibiotic treatment in 
CRBSI between patients admitted to the hospital or 
treated entirely at home.  
Adverse events 
• Incidence rate of CR-BSI was 0.9 in children.  
• Incidence rate of tunnel infection was none in 
children.  
• 4 children never developed CR-BSI. Three children 
with episodes of CR-BSI were treated as inpatients.  
• There were no adverse effects during OPIVAT 
Financial 
• The National Health System in 
Spain covers all the expenses 
due to IV nutrition both in the 
inpatient and the outpatient 
setting, including those due to 
the complications of the 
technique. 
 
• None reported. • Use of OPIVAT requires adequate 
selection criteria and patient 
evaluation. Patients must be 
medically stable, the home 
environment should be clean, have a 
telephone, etc. 
• Children develop CR-BSI more 
frequently than adults 
• When a catheter infection occurs 
antibiotic parenteral therapy may be 
administered totally or partially at 
home. Cost-savings and benefits for 
the patient may be significant. 
Cantero 
(2014)  
 
Spain  
 
 
 
Prospective 
descriptive. 
 
55 children (33 
males and 22 
females). 35 
patients (63.6%) 
had more than 
one episode = 
total of 163 
episodes of home 
parenteral 
treatment 
 
Mean age 11.1 
years 
Underlying condition  
• Cystic fibrosis, cancer, 
gastrointestinal 
diseases, HIV 
infection, 
bronchopulmonary 
dysplasia and hyper 
IgM syndrome. 
Indication for treatment  
• The main sources of 
the treated infections 
were respiratory tract 
(76%), catheter-
related bloodstream 
(9.2%), and urinary 
tract infections (5.5%).   
 
Inclusion criteria:  
• Medically stable patient 
(assessed by interview by HHU 
team),  
• chronic underlying disease,  
• non-progressing infection,  
• family support, carers 
physically & mentally able to 
provide treatment in the home,  
• home address within the HHU 
service area, has a telephone, 
running water, and 
refrigerator,  
• voluntary consent for at-home 
treatment, signed informed 
consent 
Exclusion criteria:  
• Infection can be treated orally 
or requires other inpatient 
treatment 
 
Setting  
• Home 
Delivery: 
• Long-term patients: HHU 
nurses train long term 
patient and the carer (in 
hospital) to feel to self-
administer the 
medication and evaluate 
potential complications. 
• Shorter treatments: 
HHU nursing staff 
perform home visits to 
administer the 
treatment (the patient 
and carers trained to 
assess for 
complications). 
• Daily phone call from 
HHU team while patient 
is home and treatment is 
ongoing; home visits 
from member of HHU 
team as needed.  
 
 
Key clinical outcomes 
• Most treatments (96.6%) were IV; IM route in 5 (3%) 
episodes. 
• Peripheral access (94.5%); central access only used in 
4 (2.5%) patients who had a CVC.  
• 147 episodes (90.2%) of treatment at home prior to 
discharge.  
• Mean duration of home treatment 11.05 days (SD 
5.82, range 1-25 days) 
• Cumulative number of treatment days was 1972  
Adverse events 
• Extravasation or accidental displacement of the 
peripheral line (n=12, 7.2%), phlebitis (n=5, 3%), 
exanthema or urticaria concurrent with drug 
administration (n=5, 3%), poor technique in 
antimicrobial administration due to incorrect flushing 
of the device (n=1, 0.6%), and breakdown of the 
infusion pump (n=1, 0.6%). 
• 16 patients (9.8%) episodes required admission to the 
hospital; 4 (2.5%) to poor evolution of the infectious 
process despite treatment, and 12 (7.4%) due to an 
exacerbation of the underlying disease. 
• No deaths occurred. 
Financial 
• An estimated cost-analysis found 
that the inclusion of patients in 
this programme could have 
saved up to 95% of the cost of 
conventional inpatient 
treatment 
• It is a single-centre study  
• The majority of referrals 
were CF patients.  
• Essential factors for a successful 
OPAT programme are: appropriate 
infrastructure, careful selection of 
patients, multidisciplinary staff with 
experience both in at-home care 
delivery and in the diagnosis and 
treatment of infectious diseases, 
provision of information and 
training, good monitoring of the 
patient, guaranteed 24 h a day by 
hospital to address any 
complications that may arise.  
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Doré-
Bergeron 
et al. 
(2009)  
 
Canada  
 
 
A retrospective 
cohort study using 
record review (20 
months) 
 
66 days (range: 
33– 85 days). 
 
118 infants; 67 
(56.8%) treated in 
day treatment 
centre (DTC), 51 
(43.2%) 
hospitalized.  
 
Underlying condition 
• No other conditions 
reported 
Indication for treatment 
• Urinary tract 
infections. 
• Diagnosis of urinary 
tract infection was 
confirmed for 86.6% 
of DTC patients 
• Escherichia coli was 
identified in 84.5% of 
urine cultures; 98.3% 
of isolates were 
sensitive to 
gentamicin. Six blood 
cultures (10.3%) 
yielded positive 
results, 5 of them for E 
coli. 
Inclusion criteria:   
• Children who appeared 
nontoxic, who had normal 
renal function, and who met no 
other exclusion criteria 
Exclusion criteria:  
• age of 30 days,  
• toxic appearance or 
dehydration,  
• abnormal renal function,  
• dubious parental compliance,  
• history of urinary tract surgery,  
• abnormal cerebrospinal fluid 
(CSF) findings (leukocyte count 
of 10 cells per L or protein level 
of 0.40 g/L),  
• other serious medical 
conditions. 
 
Setting:  
• DTC 
Delivery 
• All infants were initially 
assessed by ED 
pediatricians.  
• The infants were 
monitored on a daily 
basis by DTC staff until 
symptoms improved and 
culture results were 
obtained.  
• Daily visits by paediatric 
nurses trained in the 
delivery of parenteral 
antibiotic therapy on an 
ambulatory basis until 
the end of IV treatment 
• Antibiotic administered 
via peripheral IV. 
• Parents were asked to 
measure the child’s 
rectal temperature 
every 4 hours at home 
during intravenous 
treatment 
• More than one third of 
patients (36.4%) lived 20 
km from the hospital. 
Key clinical outcomes 
• Treatment with IV antibiotics in DTC lasted a mean of 
2.7 days. 
• 86.2% of patients with confirmed UITs were 
successfully treated in DTC (defined as attendance at 
all visits, normalization of temperature within 48 
hours, negative control urine and blood culture 
results, if cultures were performed, and absence of 
hospitalization from DTC).  
• Overall success of treatment was lower for young 
infants, but this result was not statistically significant. 
Adverse events 
• 7 patients were hospitalized from the DTC (n=1, 
severe concomitant gastroesophageal reflux; n=1 
right hydronephrosis). Five of 6 children with 
bacteraemia were hospitalized because of the 
positive blood culture results. N=1 with bacteraemia 
who was not hospitalized also had an uneventful 
course.  
• Minor problems with intravenous access, including 
failure to establish IV access (gentamicin was 
administered 
intramuscularly) and the need to replace the IV line 
during the course of therapy, encountered for 5 
patients (8.6%). 
• Seven of the 8 “treatment failures” were considered 
failures because of hospital admission 
Parental 
• Rate of parental compliance 
with DTC visits was 98.3%.  
 
• Long-term results (e.g., rate 
and extent of renal 
scarring) for DTC patients 
not measured. 
• Results might have been 
different in another 
context. 
• Ambulatory treatment of infants 30 
to 90 days of age with febrile UTIs 
using short-term, IV antibiotic 
therapy at a DTC is feasible. 
• This approach may reduce 
significantly the number of hospital 
admissions for UTI treatment in this 
age group. 
• Excellent parental compliance can be 
achieved in a DTC, which allows 
close medical supervision 
 
Gauthier 
et al. 
(2004) 
 
Canada  
 
 
 
Prospective, 
observational (1 
year). 
  
Parental 
satisfaction 
survey. 
 
291 episodes of 
presumed 
febrile UTI were 
diagnosed in the 
ED, of which 
212 (72.9%) were 
sent to the DTC 
 
Patients 3 months 
to 5 years of age.  
Patients treated at 
the DTC, with a 
final diagnosis of 
UTI, had a median 
age of 12.0 
months (range: 3-
68 months), 
 
Underlying condition 
• No other conditions 
reported 
Indication for treatment  
• Presumed febrile UTI 
• Children were 
considered febrile if 
their parents 
reported fever at 
home or if, in the ED, 
they had a body 
temperature of 38.5°C 
rectally or 38°C orally.  
Exclusion criteria:  
• Toxic appearance,  
• 5% dehydration,  
• dubious parental compliance,  
• parental inability to comply 
with the physical requirements 
of treatment at the DTC or 
parental refusal,  
• known significant uropathy,  
• history of surgical intervention 
involving the urinary tract 
during the past 3 months,  
• hearing deficit,  
• abnormal serum creatinine 
levels,  
• other serious medical 
conditions.  
 
Setting:  
• DTC 
Delivery 
• Evaluation performed in 
the ED included a 
complete blood count, 
blood culture, 
measurement of serum 
blood urea nitrogen, 
creatinine, 
and electrolyte levels, 
urinalysis, and urine 
culture. 
• IV antibiotics 
administered via 
peripheral line. 
• Parents were given 
written information 
about follow-up care at 
the DTC 
 
 
Key clinical outcomes 
• Duration of IV antibiotic therapy at the DTC was 1.9 
days (SD: 0.9 day).  
• Mean number of visits to the DTC, including 
appointments for renal US and voiding 
cystourethrography evaluations, was 3.5 (SD: 0.9).  
• Parents were present at all scheduled visits in 98.9% 
of cases.   
• Parents refused referral to the DTC or were judged 
unable to comply with DTC treatment by ED 
physicians in only 9 instances; so children 
hospitalized. 
• Patients afebrile by 24 hours in 52% of UTI episodes 
and by 48 hours in 82%.  
• At telephone follow-up assessments 14 days after 
discharge, no patient had been rehospitalized 
because of UTI.  
• Successful treatment at the DTC (defined as 
attendance at all visits, normalization of temperature 
within 96 hours, negative control urine cultures, if 
performed, and absence of hospitalization from the 
DTC) observed in 96.6% of the 178 UTI episodes.  
Adverse events 
• Minor problems with IV access occurred in 9.0% of 
cases.  
• Four patients hospitalized from the DTC, only 1 case 
related to UTI treatment.  
• Problems with IV access occurred in 16 instances 
(9.0%) (e.g., failure to establish IV access, need to 
reinstall IV access).during the course of therapy. No 
major IV complications reported 
Financial 
• The average daily cost for 
hospitalization on the wards 
where children with UTI are 
usually admitted estimated at 
CAN $400 (US $300) vs daily cost 
for treatment at the DTC was 
CAN $52 (US $39); these rates 
did not include medication, 
investigation costs, and 
physician fees, which would be 
approximately the same in both 
settings.  
Parental 
• 172 anonymous parental 
satisfaction questionnaires 
returned: 75% described the 
overall experience at the DTC as 
excellent, 20.3% as very good, 
and 3.5% as good. Only 2 
parents (1.2%) considered their 
experience fair or poor. Of 43 
parents whose child had been 
hospitalized in the past, 65.1% 
thought that their experience at 
the DTC was much better than 
their hospital experience, 20.9% 
that it was better, and 9.3% that 
it was similar. 32% and 20.4% 
expressed worry at the thought 
of going home with a child who 
was still febrile and who had 
indwelling IV access, respectively 
 
 
 
 
 
 
 
• None reported. • Ambulatory treatment with IV 
antibiotics, at a DTC, may be used for 
at least three-fourths of UTIs among 
febrile children 3 months to 5 years 
of age.  
• DTC treatment is safe and feasible 
and appears very satisfactory to 
parents. 
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Glackin 
et al 
(2014)  
 
Ireland 
 
 
 
 
 
Retrospective 
record review (3 
years) 
 
32 children who 
received a total of 
361 OPAT courses.  
 
 
The median age 
was 8.8 years 
(range 2.75- 17.8 
years). Sixteen 
(50%) were male 
Underlying condition 
• Cystic fibrosis (n=30), 
recurrent pneumonia 
(n=2). 
Indication for treatment 
• All children treated 
with OPAT had 
pneumonia. 
• Common organisms 
included 
Pseudomonas 
aeruginosa (mucoid 
and non-mucoid), 
Staph aureus 
(methicillin sensitive 
or methicillin 
resistant), 
Haemophilus 
influenza, 
Streptococcus 
pneumonia or a 
combination.  
 
Inclusion criteria 
• Usual practice stated to be 
individual assessment by 
consultant respiratory 
paediatrician and CF nurse 
specialist for suitability for 
home IV antibiotics 
 
Setting 
• Home  
Delivery 
• The CF nurse specialists 
train parents 
(administration, storage 
of medications, hygiene, 
IV access care, 
monitoring for all 
potential side effects, 
plan of action in the 
event of same including 
names and contact 
numbers at the hospital.  
• Parent training time to 
reach competency in 
OPAT administration etc. 
was 3-5 days, while re-
training was usually < 1 
day.  
• All patients had 24hr 
access to medical 
assistance either directly 
or over the phone with 
the respiratory team or 
via the in-house medical 
registrar.   
Key clinical outcomes 
• 3,688 days of intravenous antimicrobials 
administered at home using the OPAT programme. 
• On average, children had 11 courses (range 2-112) 
over the 3 year period, with a mean duration of 10 
days therapy (range 2-42 days).  
• 23 (72%) of children treated with OPAT had 
portacaths, the remainder used long lines sited by the 
hospital IV team.  
• For children on the active lung transplant list, some 
courses were extended to 4-6 weeks with a change in 
antibiotic choice after 2-3 weeks. 
Adverse events  
• 3 (2%) portacath infections. All three were surgically 
removed after failure to respond to antimicrobial 
therapy while awaiting surgery.  
• One (0.6%) re-admission: a child who had a 
deterioration in pulmonary status and chest 
radiograph findings.  
• None reported 
 
• None reported 
 
• Patient benefits include reduced risk 
of health care associated infections 
and higher levels of satisfaction with 
OPAT (in appropriate conditions) 
than with inpatient hospital care  
• Success of OPAT is dependent on 
appropriate patient selection, 
weekly follow up of patient clinical 
status, blood tests, 24 hour access to 
medical advice and overall 
adherence to national practice 
guidelines.  
• CF is suited to OPAT because 
chronicity of condition and need for 
repeated courses of antimicrobials 
parents become trained and 
experienced, children and families 
are well known to the respiratory 
team and many of these children 
have permanent indwelling IV access 
(portacaths) in place. 
• In current climate of budget cuts, 
pressure on inpatient bed availability 
and risk of nosocomial infections, 
OPAT is an important and effective 
tool 
Goldman 
et al. 
(2017) 
  
USA 
Record review of 
the Truven 
MarketScan 
Medicaid claims 
database (4 years) 
 
Paediatric 
Medicaid 
enrollees (aged 0-
18 years). 
 
3433 distinct OPAT 
episodes for 2687 
patients. 
 
 
Underlying condition 
• No specific conditions 
reported 
Indication for treatment  
• Infections related to 
haematology/ 
oncology, 
gastrointestinal/ 
genitourinary cystic 
fibrosis, 
osteoarticular, and 
pulmonary, 
bacteraemia, 
vascular/endocarditis, 
upper respiratory 
infection, soft tissue 
infection, central 
nervous system, 
urinary tract infection, 
other. 
• Not reported Setting 
• Not reported 
 
 
Adverse events 
• More than one third of children receiving OPAT (n = 
1289; 38%) had either an ED visit or hospitalization 
during an OPAT episode.  
• Haematology/oncology diagnostic category was 
associated with the highest percentage of medical 
care encounters with 28% experiencing an ED visit 
and 51% having a hospitalization during an OPAT 
episode.  
• Other categories with high rates of healthcare 
encounters were endovascular/endocarditis (27% ED, 
24% hospitalization) and GI/GU (24% ED, 30% 
hospitalization).  
• Overall, 61% of acute healthcare encounters during 
OPAT episodes were likely attributable to a catheter-
related complication; this rate was relatively 
consistent across diagnostic categories 
• Among children who experienced an OPAT-related 
complication, 25% were treated with a highly 
bioavailable antimicrobial. 
• Of the 791 episodes of OPAT-related inpatient or ED 
use, 265 (33%) included ICD-9 code for fever, 276 
(35%) included ICD-9 code for line complication, and 
250 (32%) included ICD-9 codes for both fever and 
line complication over 20% of OPAT episodes resulted 
in children requiring medical care in the hospital or 
ED setting for an OPAT complication 
• None reported • Findings may not be 
generalizable to other US 
regions or commercially 
insured children. 
• Unable to determine the 
population-based incidence 
of OPAT as database does 
not provide the total 
population of Medicaid 
enrollees. 
• A conservative approach to 
defining OPAT may have 
resulted in an 
underestimation of the 
number of children 
prescribed OPAT.  
• Lack of chart review may 
have resulted in 
misclassification of 
indication for OPAT, 
reasons for subsequent 
healthcare use, and 
appropriateness of OPAT.  
• An overestimation of the 
complication rate by 
including fever may be 
reason for high OPAT 
complication rate (ED visit 
or hospitalization) 
 
 
 
 
 
• OPAT is used for children with a 
wide spectrum of clinical diagnoses 
and for the administration of a wide 
variety of antimicrobial agents, 
including antibacterials and 
antifungals.  
• A substantial number of OPAT 
episodes included highly bioavailable 
antimicrobials prescribed 
intravenously that could potentially 
have been administered orally.  
• Patients receiving OPAT are at high 
risk for requiring additional ED and 
inpatient hospitalizations during 
their OPAT episode, and the majority 
of these healthcare encounters were 
likely related to OPAT complications 
• Failure to switch from OPAT to oral 
administration when using highly 
bioavailable agents can result in 
higher medical care cost and the 
potential for harm without evidence 
of therapeutic benefit 
• The high cost and potential for 
complications means additional 
studies are needed to compare the 
effectiveness of OPAT to oral 
therapy for other conditions as well 
as comparisons between longer and 
shorter durations of IV therapy 
• The integration of stewardship 
principles into clinical decision 
making prior to OPAT initiation 
is critical.  
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Gomez et 
al. (2001) 
 
USA 
 
 
Retrospective 
record review (4.5 
years) 
 
229 patients 
received 237 
courses of OPAT 
 
Mean age of 8 
years (median, 8 
years; range, 14 
days to 19 years).  
 
Majority of 
patients were 
male [127 (55%)] 
and Caucasian 
[170 (74%)]. 
Underlying condition 
• No specific conditions 
reported 
Indication for treatment  
• Many different types 
of infections were 
treated with OPAT, 
musculoskeletal 
infections remained 
the most commonly 
treated infection. 
 
•  Not reported. 
 
Setting 
• Home 
Delivery 
• Since study was 
retrospective, medical & 
social criteria used in 
patient evaluation for 
OPAT could not be 
reviewed. 
• However, usual practice 
reported as follows: 
prior to discharge, family 
and the home situation 
evaluated and at least 2 
family members trained 
(administration, catheter 
management, catheter-
associated complications 
and adverse drug 
reactions).  
• Usual practice, initial 
daily nurse visits, then at 
least once a week while 
OPAT was administered. 
And patients seen at 
least once every week or 
every other week, and 
weekly laboratory tests 
were done 
 
Key clinical outcomes 
• Primary IV access included central venous catheters 
for 125 (53%) courses, peripherally inserted central 
catheters for 99 (42%), peripheral IV catheters for 7 
(3%) and unknown for 6 (2%) courses. The use of 
peripherally inserted central catheters increased 
from 33% in 1995 to 59% in 1998.  
• During the review period: OPAT use increased by 
almost 4-fold; patients <=2 years of age, showing a 7-
fold increase;  
• 42 (18%) patients <=1 year of age and 1 (0.4%) <=1 
month of age received OPAT during the study period.  
• Average post-OPAT follow-up period was 8 weeks 
(range, 1 to 67 weeks). The mean duration of therapy 
(31 days) 
Adverse events 
• Average time to developing catheter-associated 
complications was 22 days.  
• Catheter-associated complications (CAC) prompted 
cessation of OPAT in 17 (7%) courses.  
• Adverse drug reactions (ADRs) developed in 70 (29%) 
OPAT courses and prompted early discontinuation of 
antibiotics in 58 (24%). Both ADRs and CACs 
developed in 20 (8%) OPAT courses.  
• Average time to ADRs was 19 days (range 1–71 days).  
• Rehospitalization was necessary for 62 (26%) OPAT 
courses. CACs and catheter changes prompted 
rehospitalization in 26 (42%) courses, ADRs in 17 
(27%), surgery for treatment of primary disease in 18 
(29%) and various other causes in 5 (8%). A few 
patients were rehospitalized more than once or had 
more than one reason for rehospitalization. 
• None reported • Quality of life issues during 
OPAT could not be 
addressed in this 
retrospective analysis. 
• Further studies are needed to gain 
insight into the impact of OPAT on 
patients’ and families’ lives. 
• Close monitoring of potential 
complications is needed.  
• Medical and social criteria must 
apply when identifying suitable 
candidates.  
• Paediatric guidelines for OPAT 
similar to adult guidelines need to be 
established.  
Gutpa et 
al. (2009) 
 
INDIA 
 
 
 
 
 
 
 
Single 
institutional, 
randomized 
control trial of  
oncology children 
with low-risk 
febrile 
neutropenia 
(LRFN) 
 
 
88 patients (67 
males, 21 females) 
with 123 episodes 
of OPAT (62 
randomised to 
oral arm; 61 to IV 
arm). Median age 
was 8.25 years 
(oral) and 7.75 
years (IV) 
Underlying condition 
• Acute lymphoblastic 
leukaemia,  primitive 
neuro-ectodermal 
tumour, 
rhabdomyosarcoma 
and osteosarcoma 
Indication for treatment 
• Low-risk febrile 
neutropenia (LRFN) 
 
Inclusion criteria 
•  patients with age 2-15 years; 
absolute neutrophil count 
(ANC) r500/mL;  
• normotensive;  
• no clinical evidence of lower 
respiratory tract infection;  
• normal chest radiograph;  
• presence of reliable caretakers,  
• availability of telephone 
contact  
• residence less than 1 hour from 
the medical centre.  
Exclusion criteria 
• Conditions normally requiring 
hospitalization (e.g., such as 
dehydration, severe mucositis, 
pneumonia, typhlitis);  
• intensive leukaemia/ 
lymphoma treatment except 
maintenance therapy in acute 
lymphoblastic leukaemia;  
• stem cell transplantation;  
• refractory malignancy; 
• renal insufficiency;  
• severe biochemical 
derangements; 
• hepatic dysfunction;  
• neutropenia predicted to last 
more than 10 days after onset 
of fever;  
• past history of invasive fungal 
infections 
 
 
 
Setting:  
• Outpatient clinic of 
study hospital or nearby 
medical clinics. 
Delivery 
• Patients were instructed 
to record their 
temperature at home 3 
times daily and bring the 
temperature charts to 
the clinic every 24 to 48 
hours or as often as 
indicated by the clinical 
condition where they 
were assessed clinically 
and complete blood 
count was checked.  
• If unable to come at 24 
hours, a phone call was 
made to ensure the 
stability of the patient. 
 
Key clinical outcomes 
• There were 27.1% episodes in the oral arm and 24.1% 
episodes in the intravenous arm with no documented 
focus of infection.  
• Treatment of FN was successful in 55/61 (90.16%) 
episodes in oral arm and 54/58 (93.10%) in IV arm.  
Adverse events 
• 3 hospitalizations (all in the oral arm; seizures, 
bleeding and nonresolution of fever in one patient 
each) and no mortality.  
• In the 4 patients excluded from analysis there was no 
mortality and all underwent successful therapy of 
their episodes of FN. Three of the 4 excluded patients 
had inadvertently received cefoperazone-sulbactam 
instead of ceftriaxone. 
• There were 6 failures in oral and 4 failures in the 
intravenous arms. Subgroup analysis revealed that 
failure was associated with diarrhoea in the IV arm 
and use of oral therapy in RMS patients receiving 
VAC. 
• None reported • Study was underpowered 
to draw conclusions about 
mortality (extremely low-
risk/low-incidence event in 
this group of patients) 
• Careful selection of patients is 
important: patients with controlled 
disease,  
• clinically well, reliable caretakers and 
whose home was less than 1-hour 
journey from the hospital 
•  Maintaining daily telephone contact 
with the patient. helps in monitoring 
patient progress when patients are 
unable to attend clinic daily, in times 
of emergency and also helps to 
ensure patient compliance.  
• The risk factors significantly 
associated with failure in our study 
could help in refining criteria for 
pediatric LRFN and planning further 
studies.  
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Hodgson 
et al. 
(2016)  
 
 
Australia  
 
 
Prospective, 
observational (12 
months). 
 
228 patients 
received OPAT in 
251 episodes. 
 
Median age: 7.4 
years (range 1 
week to 
21 years); 22 
patients (10%) 
under 1 year 
 
 
Underlying condition  
• Most patient referrals 
from inpatient wards; 
general medicine (55, 
24%), haematology/ 
oncology (38, 17%), 
respiratory (29, 13%) 
orthopaedics (25, 
11%) 
• 42(18%) were referred 
directly from the 
emergency 
department (ED).  
Indication for treatment 
• Most frequent 
diagnoses for which 
patients received 
OPAT were 
exacerbation of cystic 
fibrosis and urinary 
tract infection (UTI). 
• Of the 42 admitted 
directly from the ED, 
the majority were for 
skin and soft-tissue 
infection (25, 60%) 
and UTI (14, 33%). The 
remaining few were 
pneumonia worsening 
despite oral 
antibiotics, CLABSI and 
septic arthritis 
•  Setting 
• Home 
Delivery 
• All antibiotics were 
administered by trained 
nurses, not parents. 
• Central venous catheter 
(CVC) care was 
consistent with hospital 
guidelines: no-touch 
sterile technique, 
dressings changed every 
seven days and 
inspection daily to 
identify insertion-site 
infection. 
• Antimicrobial agents 
were administered 
either through 24 h 
elastomeric infusers as a 
short push or using 
pumps over a defined 
time frame.  
• Visits by HITH nurses 
occurred daily or twice 
daily depending on the 
antibiotic prescribed.  
 
 
 
 
 
 
 
 
 
 
 
Key clinical outcomes 
• In total, 309 parenteral antibiotics prescribed: 304 IV, 
3 IM and 2 IV followed by IM. Simultaneously, 57 
patients also had an oral antibiotic and 1 an 
intranasal antibiotic prescribed. 
• Overall, only 1 of 251 OPAT episodes was abandoned 
due to persistently positive blood cultures. All others 
had resolution of infection by the end of the OPAT 
course or improvement sufficient to switch to oral 
antibiotics to complete the course. 
• Venous access was most commonly peripherally 
inserted central catheter (29%) and peripheral 
cannula (29%).  
• Median length on OPAT was 7 days (range 1–190 
days), varied between conditions.  
• Shortest lengths of OPAT (median of 1–2 days) were 
for skin abscess, cellulitis, community-acquired 
pneumonia and UTI.  
• Longest lengths of stay (median >21 days) were for 
ascending cholangitis, pyomyositis, chronic 
osteomyelitis, discitis and cerebral abscess. 
Adverse events 
• Majority of antibiotics (72%) were prescribed 
appropriately but 6% deemed an inappropriate 
choice for the indication and 26% had inappropriate 
dose or duration  
• Incidence of central line-associated bloodstream 
infections was 0.9%.  
• Unplanned readmission rate was 4%, with low rates 
of OPAT-related adverse events. Three children (1%) 
had an inadequate clinical response.  
• OPAT-related adverse events were all related to 
vascular access with an overall access complication 
rate where it was recorded of 11% (14/133): 
CVC/portacath 4/45 (9%), PICC 4/46 (9%), peripheral 
cannulae 3/26 (11%) and midline catheters 3/7 (43%).  
• No antibiotic adverse events necessitating change or 
cessation of antibiotic or hospital readmission. 
Financial 
• Reduction in cost to care for a 
patient at home receiving OPAT 
compared with the average cost 
of care in a hospital bed  in study 
hospital for a medical patient is 
AU$590/day.  
• As there were 3084 days where 
OPAT replaced inpatient care, 
this represents an estimated 
cost saving of AU$1.82 million in 
1 year. 
• This study did not 
directly compare 
outcomes of OPAT 
with inpatient 
antimicrobial 
therapy, and these 
groups may be 
different. 
• In this study population, OPAT 
appears to be safe (few adverse 
events), efficacious (low rate of 
unplanned readmissions) and cost-
effective (cheaper than an 
equivalent inpatient bed stay). 
• Room for improvement in 
documentation, drug monitoring and 
appropriateness and the 
development and implementation of 
an OPAT-specific guideline and 
increased oversight of antimicrobial 
use will be important.  
• Depending on clinical response, 
children can still attend school or 
nursery, limiting educational 
interruptions, and parents can 
therefore attend work 
• Overall complication rate for 
PICC, CVC and portacaths 
combined was 9%, and it is 
not clear why this rate is so 
much lower. It may reflect 
different selection criteria for 
patients related to high rate 
of peripheral cannula use, 
strong hospital education 
from the Infection Control 
team about CVC care or 
possibly under-reporting of 
complications. 
Le et al. 
(2010)  
 
USA  
 
 
Retrospective 
record review (6 
years) 
 
98 patients (under 
age 18) who had 
received care from 
Memorial 
Home Health Care 
Agency 
 
Underlying condition 
• Not reported 
Indication for treatment 
• osteomyelitis, septic 
arthritis, pneumonia, 
cystic fibrosis-related 
pneumonia, and 
skin/soft-tissue 
infections 
 
 
 
Inclusion criteria 
• patients should have received 
OPAT for at least 1 day at 
home.  
Exclusion criteria 
• Patients with cancer, sickle cell 
anaemia and 
immunodeficiency were 
excluded 
 
Setting 
• Home 
Delivery 
• Home health nurses 
provided instructions on 
catheter care and 
antibiotic administration 
and, in conjunction with 
clinicians, determined 
the need for return to 
the ED or hospital to 
address any CACs. 
Key clinical outcomes 
• Approx. 14% of patients did not have an organism 
identified, making it difficult to transition to 
appropriate oral therapy. However, for infections like 
osteomyelitis and septic arthritis which are usually 
caused by Gram-positive organisms, an oral antibiotic 
such as linezolid, though expensive, may be more 
cost-effective and safer than placing a PICC line and 
monitoring through a home health agency. 
Adverse events 
• A total of 36 complications occurred in 32 of 98 
patients receiving a course of OPAT.  
• 25 catheter associated complications (CACs) e.g., 
Occlusion/clotting (n = 9) and dislodgement (n = 8)  
and 11 antibiotic associated complications (AACs) e.g. 
neutropenia (n = 5).  
• The mean time to development of a complication was 
7 days (range 1-28 days) after PICC placement;  
• The use of OPAT for osteomyelitis was associated 
with complications (odds ratio = 2.69; 95% 
confidence interval = 0.99-7.35; P = .05). 
• Interruption of OPAT from complications resulted in 
early discontinuation of IV antibiotics.  
• 17 patients required an unplanned medical care visit 
to the ED, hospital, or clinic: 15 with CACs and 2 with 
AACs. 2 were hospitalized to complete a course of IV 
antibiotics.  
• Not reported 
 
 
 
 
 
 
• As the standard of care in 
study hospital was OPAT, 
there was no control group.  
• Retrospective design 
meant could not fully 
capture the social impact of 
OPAT, including patients’ 
return to school or parents’ 
return to work.  
• Unable to conduct long-
term follow-up on these 
patients or determine if 
patients went to an outside 
facility for complications 
• OPAT therapy was effective, but a 
third of children on OPAT 
experienced complications and often 
required additional health care visits. 
• Further studies in children with 
prospective designs are needed to 
evaluate the social impact of OPAT 
and the role of alternative 
approaches to OPAT including the 
use of oral antibiotics with good 
bioavailability and activity against 
MRSA in the outpatient setting.  
• Evaluation of the costs associated 
with complications from OPAT is 
needed and should incorporate visits 
to the ED and clinics, and 
rehospitalization. Although OPAT is 
more cost-effective than 
hospitalization, it may still be more 
expensive than oral antibiotic 
therapy and may not offer any 
additional benefit.  
• Given that one third of children 
experienced complications and half 
of them required medical attention, 
alternatives to OPAT should be 
explored. 
•  
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Madigan 
& 
Banerjee 
(2013)  
 
USA  
 
 
Retrospective 
record review (16 
months) 
 
109 unique 
patients received 
OPAT; 13 (12%) 
patients received 
2 or more OPAT 
courses 
 
The mean patient 
age was 8.8 years 
(range: 1 month–
20 years), and 
there was an equal 
distribution of 
males (n = 63, 
50%) and females 
(n = 63, 50%). 
Underlying condition  
• Not reported 
Indication for treatment 
• Most common 
conditions: bone and 
joint (21%), 
bloodstream (15%), 
intra-abdominal (13%) 
and soft tissue (9%) 
infections. 
 
Inclusion criteria 
• Providers, together with nurses 
and pediatric discharge 
planning specialists assessed 
stability of the home 
environment and ability of 
parents or guardians to 
administer medications before 
discharge with OPAT. 
• The home healthcare nurse 
provided teaching of parents or 
guardians before hospital 
discharge or at the first home 
visit that generally occurred on 
the day of discharge. Catheter 
flushing instructions were 
dependent on home healthcare 
agency and catheter type.  
Exclusion criteria 
• If there were any concerns 
regarding patient compliance 
or suitability of the home 
environment for OPAT, OPAT 
was generally not used.  
 
Setting 
• Home 
Delivery 
• Agents were usually 
infused through pushes, 
24-hour pumps, or 
Intermate infusion 
systems.  
• Catheter dressing 
changes were 
performed once weekly 
by the home healthcare 
nurse.  
• Patients followed by the 
ID service were seen for 
follow-up in the 
outpatient pediatric ID 
clinic where potential for 
transition to oral agents 
was assessed.  
 
 
Key clinical outcomes 
• Of 123 OPAT courses with follow-up, 109 (88.6%) 
resulted in cure, 13 (10.6%) were treatment failures 
and 1 (0.8%) resulted in OPAT discontinuation 
because the patient did not have an infection.   
• The median duration of OPAT was 12 days.  
• Of 107 courses where OPAT was used for 7 or more 
days, median duration was 14 days (mode: 12 days, 
range: 7–51 days). The median duration of OPAT was 
longest for treatment of hardware infections (38 
days), endovascular infections (31 days) and bone 
and joint infections (20.5 days).  
• Shorter durations were used to treat intra-abdominal 
infections (14 days), skin and soft tissue infections (14 
days), catheter-related bloodstream infection (12 
days), urinary tract infection/pyelonephritis (12 days), 
complicated pneumonia  
• Treatment failures occurred in patients with catheter- 
related bloodstream infections (n = 1), hardware 
infections (n = 2), intra-abdominal infections (n = 2), 
central nervous system infection (n = 1), complicated 
pneumonia (n = 1) and complicated pyelonephritis (n 
= 1). 
Adverse events 
• Thirty-six courses (29%) resulted in catheter- or 
antibiotic-associated complications. Catheter-
associated complications (CACs) were less common 
than drug-associated complications.  
• CACs included infection, blockage, development of a 
deep venous thrombosis, dislocation and pain 
occurred exclusively in patients with PICC lines and 
those being treated for bone and joint, endovascular 
and skin and soft tissue infections  
• Antimicrobial-associated complications occurred 
most frequently in patients with bone and joint 
infection, catheter-related bloodstream infection and 
intra-abdominal infections and in those receiving 
cefazolin, piperacillin/ tazobactam and vancomycin.  
• Among 35 patients with complications, 17 (48.6%) 
had 1 or more unscheduled visits to the emergency 
department or other healthcare providers, and 8 
(22.8%) required rehospitalization 
Financial 
• The complications in children 
receiving OPAT also raise 
concern about the actual cost-
effectiveness and caregiver 
satisfaction of OPAT in children, 
which deserves further study 
 
• A retrospective, single 
• center study over a short 
time frame.  
• There were few OPAT 
patients not followed by 
the paediatric infectious 
disease (ID) service, limiting 
ability to discern 
differences in outcomes 
between patients with and 
without ID involvement.  
• Definitions of some 
complications were 
somewhat subjective (e.g., 
hepatitis), and may not 
have prompted all 
providers to make 
modifications to 
antimicrobial therapy. 
 
• Overall cure rate of 89% is slightly 
lower than previous 
reported rates between 96% and 
99%. These differences may be 
explained by the fact that study 
included lengthier follow-up time 
and included patients with 
heterogeneous syndromes including 
difficult to eradicate hardware 
associated infections. 
• Opportunities to increase the role of 
pediatric infectious disease in OPAT 
initiation and management should 
be explored  
• Despite ample literature describing 
OPAT or PICC line-associated 
complications many providers 
initiating and managing OPAT 
underestimate the associated risks. 
There is a need to increase provider 
and patient education about risks 
associated with OPAT in children.  
• The complications in children 
receiving OPAT also raise concern 
about the actual cost-effectiveness 
and caregiver satisfaction of OPAT in 
children, which deserves further 
study 
• In this study and others, catheter-
related complications were generally 
seen in children treated for more 
than 2–3 weeks, suggesting that 
shortening the duration of OPAT and 
converting to oral therapy sooner 
might reduce OPAT complication 
rates 
• Opportunities to increase 
involvement of pediatric ID or 
antimicrobial stewardship groups in 
OPAT initiation and management 
should be explored. 
 
Maraqa 
et al. 
(2002)  
 
USA  
 
Retrospective 
record review 
 
179 patients with 
osteoarticular 
infections (OAIs); 
total of 184 
episodes. 
 
Average age was 
8.25 years 
(median 8 years; 
range 3/12 - 18 
years); 100 
(54%) were male 
Underlying condition 
• No associated 
conditions reported 
Indication for treatment 
• OAIs included 116 
(63%) acute 
osteomyelitis, 42 
(23%) septic arthritis, 
and 26 (14%) chronic 
osteomyelitis. 
• Among patients with 
osteomyelitis, 23 
(16%) had 
concomitant septic 
arthritis 
 
• Not reported Setting 
• Unclear.   
Delivery 
• While on OPAT, patients 
were followed weekly, 
and a nurse performed 
weekly laboratory tests 
looking for OPAT-related 
complications. 
• Patients’ caregivers had 
24-hour access to on-call 
physicians in both 
specialties.  
 
Key clinical outcomes  
• OPAT was given through 110 (59.8%) CVLs, 71 
(38.6%) peripherally inserted central catheters 
(PICCs), and 3 (1.6%) peripheral cannulas.  
• OPAT courses were completed in 118 (64%) OAIs. 
• Average length of therapy for acute osteomyelitis 
was 42.2 days. Average length of therapy for septic 
arthritis was 29.6 days. Patients with chronic 
osteomyelitis received an average of 58 days of 
parenteral therapy, followed by oral antibiotic 
therapy  
Adverse events 
• Three OPAT courses had both mechanical and 
infectious complications (2 CVL, 1 PICC). 
• Infectious complications included 13 cases of local 
exit-site infection: 10 CVL, 3 PICC, and 4 cases of 
bacteremia (2 CVL, 2 PICC).  
• The overall rate of infectious complications was 2.7 
per 1,000 catheter-days. The average time to 
development of infectious complications was 24.5 
days.  
• Non-catheter-related OPAT complications were 
mostly due to adverse drug reactions (92%) occurring 
in 60 (32%) courses .   
• Rehospitalization during OPAT occurred in 48 (26.1%) 
courses: 28 CVL (26.3%) and 20 PICC (26.7%). 
• None reported 
 
• None reported • Whenever possible, a PICC line 
should be used since it is safe to use 
in children 
• Patient selection for OPAT should 
take into consideration family 
readiness and acceptance, the 
presence of a suitable home 
environment, as well as issues of 
reimbursement 
• An improvement in the quality of life 
of both the children and their 
families was reported. 
• IOPAT had an excellent rate of 
clinical cure and a low rate of 
complications for management of 
childhood osteoarticular infections.   
• Although oral therapy of OAIs may 
be preferable, OPAT provides an 
effective and safe modality of 
therapy, especially if compliance or 
bioavailability of oral agents is a 
concern.  
• To ensure a good outcome, a team 
approach is necessary where 
caregivers are active participants in 
management and a supportive 
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• Rehospitalizations were most commonly due to 
adverse drug reactions, followed by catheter-related 
mechanical complications and further surgical 
management.  
• Clinical cure occurred in 168 (97.6%) of 172 evaluable 
OAIs. Twelve (6.5%) courses were nonevaluable due 
to ongoing therapy or loss to follow-up. Of the four 
(2.2%) OAIs that failed treatment, one had recurrence 
and three had persistence of infection 
medical team is accessible at all 
times 
Author, 
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Orme et 
al  (2014) 
 
Australia 
 
An unblinded 
randomised 
controlled trial 
comparing  
 
Range age: 1.95–
16.92 
 
N=27, 18 
inpatients, 19 
outpatients 
 
Fever and neutropenia in 
children receiving 
chemotherapy for 
malignancy. 
Inclusion criteria 
• Resided within 1 hour travel 
time (or 30 km radius) with 
appropriate transport and 
telephone 
Exclusion criteria 
• AML or mature B-cell 
lymphoma 
• Patients in the induction phase 
of ALL or receiving 
predominantly high dose stem 
cell-supported chemotherapy 
• History of allergy to penicillins 
or cephalosporins  
• families who were non-English 
speaking. 
• Home treatment with 
Home and Community 
Care support. After 
discharge, (HACC nurses 
visited twice daily to 
provide general review 
with vital sign 
monitoring, cefipime 
administration and 
blood tests.  
• Parents of outpatients 
recorded tympanic 
temperature 4–6 hourly. 
Blood product 
transfusions (in day 
procedure centre) and 
outpatient medical 
reviews were arranged 
as deemed appropriate  
Adverse events  
There were no adverse events due to outpatient 
management per se. 
Antibiotic management was altered for the six 
outpatients who were readmitted during the course of 
FN, including change to acyclovir in one patient and 
addition of or change to amphotericin in two 
Parental 
Parent questionnaires show a 
higher level of QOL for outpatient 
care on Days 2, 3 and 4 overall, 
though these differences were not 
statistically significant. 
For children, only differences in 
sleep (7.7 vs. 5.6, P¼0.01) and 
appetite (6.2 vs. 4.4, P¼0.05) were 
significant. 
 
• The number of study 
participants was limited 
and as such the ability to 
understand safety, 
feasibility and risk 
stratification is limited. 
• Findings may reflect an 
overall bias towards an 
ultra low risk FN subset.  
• We did not track and 
record reasons for 
ineligibility and refusals of 
patients at initial 
preconsent when they 
were identified in oncology 
clinic. 
• We did not assess culturally 
and linguistically diverse 
families  
• The majority of families 
were represented in survey 
participation by the 
mother; fathers may have 
had different views. 
• Finally, the survey 
questions chosen were not 
part of a validated QOL tool 
 
 
• Further work should aim to examine 
the effectiveness of outpatient FN 
management through large cohort 
studies which may also assess the 
use of decision tools which are 
intended to facilitate ambulatory 
approaches 
Author, 
Year 
Country 
Design, 
Sample size,  
Age of children 
Underlying condition/ 
Indication for treatment 
 
Key requirements /influences on 
offering OPAT/inclusion & 
exclusion criteria  
Setting (DTC/Home)/  
Delivery 
Key clinical outcomes/adverse events (Note: for some 
papers events categorised as adverse by scoping 
reviewers)  
Other outcomes (e.g., finance, 
family perspectives) 
Author-noted 
limitations 
Author-noted comments/ 
recommendations 
 
Reid and 
Bonadio 
(2006)  
 
USA  
 
 
Retrospective 
record review (5.5 
years) 
 
29 patients 
presenting at 
Emergency 
Department (ED) 
 
Age: ranged from 
1 to 16 years. 
Underlying condition  
• No associated 
conditions reported 
Indication for treatment 
• Cellulitis (20), Lobar 
pneumonia (2), fever 
without focus (3), 
pyelonephritis (2), 
mastoiditis (1), Group 
A streptococcal 
tonsillitis (1). 
Inclusion criteria 
• Parents had to be considered 
reliable caretakers  
• Have access to transportation 
and a telephone. 
 
Setting 
• Emergency Department. 
Delivery 
• All patients were 
instructed to return to 
the ED within 24 hours 
for re-evaluation of their 
condition (follow up ED 
visit).  
• Patients with cellulitis 
had an ink line drawn on 
their skin to demarcate 
the outer perimeter of 
the infection.  
• Standard practice to 
instruct parents to 
inspect the IV site every 
4 hours and to seek re-
evaluation if there was 
swelling, redness, or 
pain of the contiguous 
skin, or if the IV catheter 
apparatus became 
disconnected.  
Key clinical outcomes 
• All patients returned for re-evaluation within 24 
hours after initial discharge. 
• 28 patients received a second dose of IV ceftriaxone 
through the original catheter and were discharged 
with a prescription for an oral antibiotic.  
• No patient required hospitalization at the time of 
follow-up ED visit.  
• For patients whose cultures subsequently grew a 
pathogen, none were resistant to ceftriaxone.  
• No patient experienced adverse event related to 
antibiotic administration (e.g, rash, diarrhoea, 
anaphylaxis). 
Adverse events 
• In one case, a parent removed the IV catheter at 
home when their child complained of 
numbness/soreness of the skin at the IV site. 
• None reported • Limited by retrospective 
design. Although no study 
patients returned to study 
hospital after their second 
visit, it is possible some 
were treated at other 
institutions for a 
deterioration in their 
condition.  
• Study population 
represents a convenience 
sample so selection bias 
may have excluded 
patients who would have 
made results less 
compelling. 
• Peripheral IV catheters for pediatric 
patients can be successfully secured 
and maintained at home by reliable 
caregivers for a period of 24 hours.  
• Use of peripheral IV catheters for 
short-term parenteral therapy for 
infectious conditions in pediatric 
outpatients seems feasible. 
• Because parents were not required 
to prepare and administer 
medication at home, the infection 
control pitfalls inherent to this 
process were avoided.  
Shemesh 
et al. 
(1998) 
 
Retrospective 
analysis (2 years) 
 
Underlying condition 
• Acute lymphocytic 
leukemia (8), Beta-
Inclusion criteria 
• Patients eligible for immediate 
discharge on HIAT were 
Setting 
• Home 
Delivery 
• Patients were examined by their oncologist during 
home therapy for a mean of one visit per 2.9 days on 
HIAT (group total, 219 office visits).  
Parental/family 
• All 24 parents and patients 
surveyed were very satisfied 
• No pilot study can 
safely recommend 
one method of 
• Results show that immediate 
discharge on HIAT is feasible 
and safe for a preselected 
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Israel 
 
Retrospective 
phone survey (re: 
satisfaction and 
adverse events) of 
patients and 
parents  
 
30 patients with 
oncology/ 
haematology 
diagnosis; 15 
female; 15 male.  
 
Treated for 60 
episodes of fever. 
 
Median age: 8 
years (range 9/12 -
19 years)  
 
 
 
thalassemia, 
splenectomized (4), 
Wilms’ tumor (3), 
Ewing’s sarcoma (2), 
B-cell lymphoma (2), 
Rhabdomyosarcoma 
(2), Other (9 
Indication for treatment 
• Febrile episode with 
low risk for septic 
complications 
 
 
 
required to meet the following 
criteria:  
• Full parental (and patient, 
when applicable) consent.  
• Previous demonstration of 
proficiency in home care (as 
judged by the designated 
nurse).  
• Less than 1 hour’s travelling 
time from the patient’s home 
to the nearest hospital. 
• The infection was probably 
community-acquired (no 
hospitalization in the previous 
48 hours).  
• No serious comorbidity existed 
that independently required 
hospitalization; no signs of 
shock. 6. The underlying 
hematologic disease was 
known and presumably 
controlled. 
• No initial evidence of 
pulmonary or central nervous 
system infection.  
• No history of drug or child 
abuse in the nuclear family.  
• The patient had a functional 
indwelling central venous 
catheter.  
• Single-parent families, families 
of low socioeconomic 
background, and Bedouin 
families (who live in tents in 
the desert but have a reliable 
fresh water source and a 
refrigerator) were not excluded 
• After the central venous 
catheter was inserted 
for HIAT, eligible 
patients and parents 
received instruction, 
under close supervision 
by a designated nurse, 
on how to administer 
the fluids or antibiotics 
and competence 
evaluated.  
• Routine follow-up was 
scheduled 3 to 4 days 
after initiation of 
therapy, or earlier if 
needed.  
• Parents were actively 
encouraged to consult 
the attending oncologist 
by phone or  consult a 
nurse or the HIAT team 
on a 24-hour basis.  
• Patients were instructed 
to present at the 
emergency room 
immediately should any 
signs of deterioration 
develop. It was explicitly 
stated that a parental 
desire for hospitalization 
was reason enough for 
admission.  
 
 
• A mean of 10.6 days of HIAT were necessary per 
episode (range, 1 to 24 treatment days), group total 
640 days.  
Adverse events 
• 13 cases (22%) led to hospitalization (unresponsive 
cases) during or shortly after HIAT.  
• Of the 42 episodes of fever without an obvious 
source of infection and neutropenia, eight (19%) 
eventually led to hospitalization. They all recovered 
after a mean stay of 8 days in the hospital.  
• Five out of 12 patients who were not neutropenic 
were eventually hospitalized (41.6%).  
• Of the 12 cases of suspected central catheter 
infection, only two (17%) led to hospitalization.  
• In all, unresponsive patients were hospitalized for a 
mean period of 21 days (range, 14 to 36 days). All 
cases recovered with no obvious sequelae.  
• Although six patients died during this 2-year period, 
none of them did so within 3 months of HIAT, and all 
deaths were clearly associated with disease 
progression. 
• Central catheter infections developed in 2 patients 
following HIAT. These patients were hospitalized, but 
it was not necessary to remove the catheters. 
• No serious adverse drug reactions were observed 
during HIAT.  
• Forty cases of fever were initially treated with 
ceftriaxone. Nine of these (23%) eventually led to 
hospitalization, four for Pseudomonas infections. 
Four of six cases who received a combination of 
ceftazidime and vancomycin (67%) were eventually 
hospitalized, two because of resistant Pseudomonas 
infection and two because of resistant catheter 
infection. Of the 10 cases who received ceftazidime 
alone, none required hospitalization. None of the 
splenectomized cases, who received cefotaxime, 
needed hospitalization. 
with home IV antibiotic therapy 
(HIAT) and wanted to use it at 
the next hypothetical episode.  
• Five of the 24 felt only partially 
competent at the first episode 
and needed expert help.  
• No one noted a specific adverse 
drug reaction, but five patients 
cited fatigue as a common 
problem during therapy. 
• None encountered serious 
mechanical problems. 
• Parental satisfaction was almost 
complete. Some parents 
indicated they were a bit 
uncomfortable and insecure on 
the first days of home 
treatment. 
• Experience suggests that it might 
prove useful to send a nurse for 
one home visit during the first 
days of treatment. 
treatment over 
another.  
•  
immune-compromised 
pediatric population.  
• A randomized, controlled, 
prospective trial is needed to 
reach valid conclusions on 
home therapy with 
hospitalization 
Author, 
Year 
Country 
Design, 
Sample size,  
Age of children 
Underlying condition / 
Indication for treatment 
 
Key requirements /influences on 
offering OPAT/inclusion & 
exclusion criteria  
Setting (DTC/Home)/  
Delivery 
Key clinical outcomes/adverse events (Note: for some 
papers events categorised as adverse by scoping 
reviewers) 
Other outcomes (e.g., finance, 
family perspectives) 
Author-noted 
limitations 
Author-noted comments/ 
recommendations 
 
van der 
Laag & 
van de 
Weg  
(1995) 
 
 
The 
Netherla
nds 
 
 
Research design 
unclear (no 
methodology 
noted); appears to 
be a retrospective 
record review (2.5 
years). 
 
15 patients at this 
hospital 33 
intravenous 
antibiotic courses 
at home  
 
The 15 home-
treated patients 
included 7 
children from 
the Wilhelmina 
Children’s Hospital 
(age range 7-17 
years).. 
Underlying condition 
• Cystic fibrosis 
Indication for treatment 
• Exacerbations of 
chronic respiratory 
infections due to 
aeruginosa 
Inclusion criteria 
• The inclusion criteria for 
training sessions are that the 
patient should: have had at 
least one intravenous antibiotic 
course in hospital within the 
last year; not have any 
complication of the disease for 
which hospitalization is 
necessary be compliant with all 
other kinds of treatment 
(physiotherapy, good nutrition, 
etc.) 
• Insurance companies agreed to 
pay for leasing an electronic 
infusion pump and elastomeric 
balloon pumps. 
• In-hospital testing of allergic 
reactions to drugs, the 
organization of home care and 
final instructions to patients 
and parents 
Setting 
• Home 
Delivery 
• Two cystic fibrosis 
(CF)nurses were 
appointed to inform and 
instruct patients and 
their families about all 
procedures concerning 
antibiotic treatment.  
• After a successful 
training a contract 
between the patient, 
parents and hospital was 
signed, in which the 
hospital agreed that 
home care was 
appropriate and 
guaranteed readmission 
in the case that home 
care failed or 
complications occurred. 
• The specialized CF nurse 
was authorised to give 
intravenous injections 
and was responsible for 
the instruction of 
patients and parents and 
control at home during 
the treatment period.  
• Prior to discharge home, 
patients treated with 
Key clinical outcomes 
• In all cases of home treatment patients improved 
their clinical condition, lung function and general 
well-being compared to former courses in hospital. 
• The home-treated children all needed frequent 
intravenous antibiotic treatment.  
• Most of the other children received only one course 
in a year; four of them have been trained for home 
treatment and will probably have this next time 
Adverse events  
• Four instances of complications during the home 
treatment periods for which a 24 h on-call service 
existed. These were: technical problems with the 
electronic pump, air bubbles in the cassettes of the 
pump due to the ceftazidime solution, and phlebitis 
for which a new venous access was needed (two 
cases). 
 
 
 
 
Parental 
• Parents, especially of those in 
the younger age group (< 12 
years), felt reluctant to accept 
such a great responsibility for 
their child’s treatment. Mothers 
were also anxious that the 
family and other siblings would 
suffer under the stress of home 
care.  Hospital admissions were 
seen to give some kind of relief 
to the family unit.  
• In the older age group (12-18 
years) the young people missed 
their daily contact with hospital 
staff and fellow patients on the 
ward but were glad to be able to 
attend their own school and to 
be at home without disruption 
of family life.  
• After a successful home-
treatment period, patients 
agreed eagerly to proposals for 
home care or even requested it 
on new admission for 
exacerbation of infections.  
• Indications for home care had to 
be considered carefully, since 10 
cases showed so much anxiety 
after a former period of home 
treatment that a further course 
• None reported • In a specialized disease like CFs 
home treatment with antibiotics 
seems feasible for a restricted 
number of patients.  
• Complications of the disease and 
anxiety of patients and parents, even 
if they have had adequate 
training and instruction, are the 
most important reasons for not 
starting home treatment. 
• Patients younger than 8 years are 
less suitable, as they do not need 
intravenous treatment very often 
and stress at home may be too great 
to have successful home treatment.  
• During the information and 
instruction phase of home care 
attention has to be paid not only to 
the technical aspects of infusion 
pumps and drug delivery, but also to 
the social and psychological issues, 
to enable the full effect of antibiotic 
treatment at home to be felt. 
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ceftazidime continuously 
in combination with 
tobramycin twice daily 
(doses adjusted after 
measuring top and 
trough levels).  
was given completely in hospital 
instead of at home 
Van 
Winkle et 
al. (2008)  
 
USA 
 
 
Retrospective 
record review (2 
years 9 months)  
 
34 patients  
 
 
The mean age 
for children in the 
group was 4.4 
years (range, 12 
days–12 
years), with 56% 
male and 44% 
female. The age 
distribution 
was relatively 
even between 2 
weeks and 12 
years of age.  
 
Underlying condition 
• 2 patients had 
leukaemia, 2 had 
cystic fibrosis, no 
other associated 
conditions reported.  
Indication for treatment 
• 30 patients had 
infectious disease 
(e.g., osteomyelitis, 
septic arthritis, 
pyelonephritis, 
resolving sepsis 
related to 
bacteraemia, cellulitis,  
appendicitis, 
mastoiditis). 
• 2 patients were 
undergoing treatment 
for leukaemia  
• 2 treated for 
exacerbations of cystic 
fibrosis 
• No detail reported apart from, 
discharge catheter care was 
provided by the Kaiser Orange 
County home health agency, 
which is directly affiliated with 
the treatment center. Between 
the home health care agency 
and the medical center, there 
was no standardized approach 
regarding this care. The care 
was provider dependent. 
 
Setting 
• Home 
Delivery 
• Between the home 
health care agency and 
the medical center, 
there was no 
standardized approach 
regarding this care.  
• The care was provider 
dependent. 
 
Key clinical outcomes 
• 33 of 34 patients completed therapy as an outpatient 
(97%).  
• 39 PICCs were placed in the 34 patients who were 
treated with outpatient parenteral antibiotic therapy 
and included in this study.  
Adverse events 
• 13 of the 39 PICCs (33.3%) had a complication 
requiring removal of the catheter. One child was 
readmitted due to accidental displacement at home. 
5 children were close to the end of therapy and 
completed it with oral antibiotics. The remaining 7 
PICCs were replaced as follows: 5 with a second PICC 
to continue outpatient therapy, and 2 with peripheral 
IV catheters to complete a brief duration of 
outpatient therapy.  
• None of the children changed to oral antibiotic 
therapy had treatment failure requiring need for 
subsequent IV antibiotics. 
• There were no incidences of phlebitis or suspected or 
confirmed catheter infection or sepsis.  
• There was a general trend toward increased odds of 
complications with PICCs placed midline (odds ratio 
12.95; 95% CI: 0.95–175.40; P 0.0540). 
Financial 
• A financial analysis was 
completed on the cost of home 
health versus the projected cost 
of hospitalization for the same 
period of time. The average daily 
cost for home health treatment 
was $115 compared with the 
average daily inpatient cost of 
$1185. 
• Total cost savings on a subset of 
26 patient episodes analyzed 
was $504,858, which was 
$19,418 per patient episode or 
$1070 per day of home health 
care for the 472 potential 
inpatient days analyzed. 
 
 
• Small sample size.  
• Results may be skewed as 
larger centers more likely 
to be treating more 
complex patients who may 
be more prone to 
complications. 
• OPAT has a significant cost savings 
over the alternative of inpatient 
treatment.  
• OPAT has a positive effect on 
hospital utilization, which is a critical 
factor in smaller paediatric wards 
where bed availability and the 
difficulty of transfer to referral 
hospitals are issues. 
Author, 
Year 
Country 
Design, 
Sample size,  
Age of children 
Underlying condition / 
Indication for treatment 
 
Key requirements /influences on 
offering OPAT/inclusion & 
exclusion criteria  
Setting (DTC/Home)/  
Delivery 
Key clinical outcomes/adverse events (Note: for some 
papers events categorised as adverse by scoping 
reviewers) 
Other outcomes (e.g., finance, 
family perspectives) 
Author-noted 
limitations 
Author-noted comments/ 
recommendations 
 
Wierniko
wski et al 
(1991) 
 
Canada 
 
 
 
Pilot programme 
(research design 
unclear) 
 
13 children  
 
Age not reported 
 
and their families 
successfully 
completed courses 
of intravenous 
antibiotic 
therapy at home. 
Seven of these 
children 
were treated on 
more than one 
occasion, giving a 
total of 22 
episodes. 
Underlying condition  
• Cancer  
Indication for treatment  
• Febrile neutropenia  
Inclusion criteria 
• Children who had indwelling 
right atrial catheters were 
eligible for the pilot program if 
they met the following criteria: 
(a) child afebrile for at least 48 
hours, after starting 
intravenous antibiotics in 
hospital; (b) child on 
appropriate antibiotic(s), as 
determined from culture 
results; (c) child clinically stable 
in the opinion of the attending 
hematologist; and (d) parent(s) 
interested, motivated, and able 
to administer intravenous 
antibiotics as assessed by the 
pediatric oncology nurse.  
 
Setting 
• Home 
Delivery 
• Child’s parent was 
instructed by a pediatric 
oncology nurse on the 
process of antibiotic 
administration, including 
aseptic technique, 
infusion procedure, 
catheter care, and 
troubleshooting.   
• Parents were required 
to give their child's 
antibiotic(s) in hospital 
under supervision prior 
to discharge, so that 
their proficiency at 
performing this task 
could be assessed by the 
pediatric oncology 
nurse.  
• The pediatric clinical 
pharmacist provided the 
parents with 
information on drug 
reconstitution, dosage, 
and side effects, and 
arranged for the supply 
of antibiotics.   
• Each family was sent 
home with enough 
antibiotics and supplies 
to complete a 10-14-day 
course of therapy as 
appropriate.  
• A follow-up 
appointment was made 
Key clinical outcomes 
• The children who received home therapy spent an 
average of 3 days in hospital followed by an average 
of 10 days at home. By comparison, the average 
length of stay for hospital treatment of febrile 
neutropenic episodes was 12 days during the same 6-
month period 
• All episodes of fever and neutropenia were treated 
successfully with home IV antibiotic therapy.  
• No reported adverse drug reactions, drug toxicity, or 
catheter complications such as occlusion, but some 
minor problems were encountered, such as shortages 
of some supplies. In every case, the shortages were 
discovered far enough ahead that additional supplies 
were obtained for the parent within 24 h.  
Parental 
• Two families met the criteria for 
entry into the pilot program, 
were instructed, but decided, 
prior to discharge, not to 
proceed and the children 
remained in hospital for 
antibiotic treatment. 
• The feedback from the parents 
who participated in this program 
was uniformly positive. 
Financial 
• Cost analysis hampered by 
inability to cost inpatient 
treatment accurately. Average 
estimated daily cost of a 
"hospital bed" (all types 
was $618; therefore, estimated 
cost of 12 days of inpatient 
therapy at $7,416 (noted to 
probably overestimates the true 
cost of such treatment).  
• Using hospital acquisition costs, 
a somewhat clearer estimate of 
the cost of home therapy 
estimated at $2,781. These do 
not include the costs that are 
borne directly by the families of 
the children.  
• The Regional Home Care 
program paid for the drugs and 
supplies that the families 
needed for home therapy during 
our pilot study. When the 
families had third-party 
coverage, the cost of the drugs 
was borne by the insurer 
• Not reported • Home IV antibiotic therapy appears 
a safe and efficacious alternative to 
hospital management of children 
with malignant diseases admitted 
with fever and neutropenia.  
• A cost analysis of the program 
indicates that home therapy is 
considerably cheaper than in-
hospital treatment.  
• However, costs for parents/families 
are expensive; especially if the 
parent must forego wages she/he 
would otherwise have earned in 
order to stay home with the child to 
administer antibiotics 
• Home IV antibiotic program for 
children with malignant disease was 
a positive experience for the children 
and the families involved.  
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to the out-patient clinic 
usually within 1 week of 
discharge.  
• In addition, 24-h on-call 
coverage was available 
to all families-a service 
we provided already. If 
the child developed a 
fever at any time while 
on home therapy, the 
family was instructed to 
bring the child back to 
hospital for re-
evaluation. 
